Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics is poised for success as evidenced by their strong launch of Icotyde in PoS, positive PK data and initiation of new programs, as well as a solid financial position with multiple low-risk future milestone payments. With a first-in-class lead asset, a strong platform, and a potentially multi-billion dollar market opportunity, Protagonist Therapeutics is undervalued and poised for continued stock outperformance. Investors should closely monitor the progress of the Ico launch and data releases from Protagonist's own programs for potential upside.

Bears say

Protagonist Therapeutics is expected to have strong upcoming milestones, including the potential FDA approval of rusfertide for polycythemia vera, which could result in significant milestone payments. However, there is ongoing competition in the market with the entry of other biologics, which could limit the success of Icotyde. The company's current positive financial situation is largely dependent on milestone payments, as their own IL-17 and obesity programs have not been included in their valuation. These factors, along with potential challenges in the market, contribute to the negative outlook on the stock.

Protagonist Therapeutics (PTGX) has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Strong Buy based on their latest research and market trends.

According to 14 analysts, Protagonist Therapeutics (PTGX) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.